文献速递妇科

卵巢癌症状与治疗关注监测量表MOST-S26的开发与验证

Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
PubMed 文献 · Gynecol Oncol · 2021-09-01

本研究在一线化疗后卵巢癌患者中开发并验证了MOST-S26量表,该量表含26个条目和5个多条目指数。726名患者每3个月完成MOST-T35等量表,结构效度(r=0.43-0.88)、区分效度和反应性均得到验证,MOST-NTx和MOST-Psych可检测症状改善,MOST-Abdo可检测复发前腹部症状恶化。

要点

  • MOST-S26含26条目和5个多条目指数,用于卵巢癌一线治疗后监测。
  • 结构效度良好(r范围0.43-0.88),区分效度符合预期。
  • MOST-NTx和MOST-Psych可检测外周神经病变和心理症状改善。

核心结论

  • MOST-S26是适用于卵巢癌一线化疗后随访监测的有效量表,能可靠检测外周神经病变和心理困扰的改善,并可能检测复发症状。

研究设计与样本

  • 前瞻性研究,纳入完成一线化疗的卵巢癌女性,每3个月完成MOST-T35等患者报告结局量表,最长3.5年。
  • 分析726名接受≥3周期化疗、3个月内未进展且完成至少一次MOST-T35的女性数据。

主要发现

  • 修订版MOST-S26含26个条目和5个多条目指数:外周神经病变(MOST-NTx)、疾病或治疗相关(MOST-DorT)、腹部(MOST-Abdo)、心理症状(MOST-Psych)和MOST-Wellbeing,外加9个独立条目。
  • 结构效度得到确认(r范围=0.43-0.88)。
  • 区分效度确认了临床 distinct 组间的预期差异。
  • MOST-NTx和MOST-Psych分别检测到外周神经病变和心理症状的改善,MOST-Abdo检测到复发前腹部症状的恶化。

临床怎么用

  • 在随访咨询中应用MOST-S26可识别令人担忧的症状,促进及时适当的干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Measure of Ovarian Symptoms and Treatment (MOST-T35) is a patient-reported symptom index, developed and validated in the context of palliative chemotherapy for recurrent ovarian cancer (OC). We aimed to develop and validate a version suitable for surveillance of symptoms following first-line treatment for OC to support clinical follow-up. METHODS: In a prospective study of women following completion of first-line chemotherapy for OC, patients completed MOST-T35 every 3 months for up to 3.5 years and other patient-reported outcome measures. Construct validity (Spearman's correlations), discriminative validity (t-tests/ANOVAs assessing differences between clinically distinct groups), ability to detect clinically important symptoms (receiver operating characteristic analysis), and responsiveness (t-tests examining change) were assessed. RESULTS: Data from 726 women who received ≥3 cycles of chemotherapy, did not progress within 3 months, and completed ≥one MOST-T35 were analysed. The revised version, MOST-S26, has 26 items and 5 multi-item indexes: peripheral neuropathy (MOST-NTx), disease or treatment-related (MOST-DorT), abdominal (MOST-Abdo), and psychological symptoms (MOST-Psych), and MOST-Wellbeing, plus 9 individual items. Construct validity was confirmed (r range = 0.43-0.88). Discriminative validity confirmed expected differences between groups. MOST-NTx and MOST-Psych detected improvements in peripheral neuropathy and psychological symptoms respectively, whereas MOST-Abdo detected worsening of abdominal symptoms pre-recurrence. CONCLUSIONS: This study developed and validated the MOST-S26, for surveillance of women in follow-up after first-line chemotherapy for OC. MOST-S26 reliably detected improvement in symptoms of peripheral neuropathy, psychological distress and may detect symptoms of relapse. Administration of MOST-S26 in follow-up consultations could identify concerning symptoms and facilitate timely and appropriate intervention.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Campbell R, King MT, Ross TL, et al. Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment. Gynecol Oncol. 2021. PMID: 34481610. doi:10.1016/j.ygyno.2021.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。